Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
Lygature, Escher, Utrecht, The Netherlands.
Drug Saf. 2018 Oct;41(10):911-918. doi: 10.1007/s40264-018-0678-7.
This article provides an overview of the current situation regarding the traceability of medicinal products, with a focus on drug safety and biologics. Limited traceability of biologics, in particular with regard to the batch number, is associated with incomplete recording of exposure information in clinical practice. The current pharmaceutical barcode standards in the EU do not support the automatic recording of dynamic product information, such as batch numbers and expiry dates, by means of electronic barcode scanning in clinical practice. New barcode requirements, such as the 2D DataMatrix with encoded batch numbers and expiry dates, provided on both the primary and the secondary package, can facilitate routine barcode scanning at all points in the supply chain in different healthcare settings. To build a full track-and-trace system for medicines with electronic capture of relevant exposure information, alignment with other topics, such as the Falsified Medicines Directive and initiatives to reduce medication errors, is needed to increase the buy-in from all stakeholders and to solve multiple issues with a joint effort.
本文概述了药品可追溯性的现状,重点关注药物安全和生物制品。生物制品的可追溯性有限,特别是在批次号方面,这与临床实践中不完全记录暴露信息有关。目前欧盟的药品条码标准不支持通过电子条码扫描自动记录动态产品信息,如批次号和有效期。新的条码要求,如主包装和次要包装上都带有编码批次号和有效期的 2D DataMatrix,可以方便在不同医疗保健环境中的供应链中的所有点进行常规条码扫描。为了建立一个具有相关暴露信息电子采集功能的完整药品追溯系统,需要与其他主题(如伪造药品指令和减少用药错误的举措)保持一致,以提高所有利益相关者的参与度,并共同解决多个问题。